City of Hope | Strategic Alliance Partners

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Paul Gellhaus, MD, discusses the clinical implications of prostate cancer screening in recognition of Prostate Cancer Awareness Month.

Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

Researchers call for early screening as young patients live longer.

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Maurie Markman, MD, raises concerns about public health priorities and resource allocation in light of the expanding role of precision medicine in cancer.

Alexey Danilov, MD, PhD, discussed how chemotherapy-free regimens have influenced treatment decision-making for patients with mantle cell lymphoma.

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

Dr Danilov highlights advances and questions in the management of mantle cell lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma.

Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

Hope S. Rugo, MD, discusses key considerations and unanswered questions arising from the DESTINY-Breast09 trial in HER2-positive breast cancer.

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Maurie Markman, MD, explores the key role of clinical judgment in treatment decision-making and its impact on patient outcomes in cancer research.

Alexis LeVee, MD, discusses clinical trials investigating ADCs that may change treatment standards for patients with various subtypes of breast cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Alexis LeVee, MD, discusses ongoing trials investigating immunotherapy agents and antibody-drug conjugates that may challenge the current SOC for TNBC.

The FDA approved frontline retifanlimab/chemotherapy for metastatic SCAC and retifanlimab monotherapy for metastatic SCAC with progression on chemotherapy.

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

Maurie Markman, MD, discusses the complexities of cancer care financing in the US, highlighting the need for innovative solutions amidst rising costs.

Hope S. Rugo, MD, has led key breast cancer therapy trials and exudes a passion for serving patients.